Generic Medicine Info
Treatment of status asthmaticus, other acute episodes of asthma or COPD. Monotherapy in asthma treatment.
Special Precautions
Patient w/ CV disease, CNS disorders, hyperthyroidism, hypokalaemia, DM, phaeochromocytoma, seizure disorder. Not intended for the relief of bronchospasm. Pregnancy and lactation. Patient Counselling This drug may cause dizziness and other similar effects, if affected, do not drive or operate machinery. Monitoring Parameters Monitor pulmonary function, BP, heart rate, CNS stimulation; serum glucose and K levels.
Adverse Reactions
Asthma: Viral infection, bronchitis, chest infection, dyspnoea, chest pain, tremor, dizziness, insomnia, tonsillitis, rash, dysphonia, serious asthma exacerbation. COPD: Upper resp tract infection, back pain, pharyngitis, chest pain, sinusitis, fever, leg cramps, muscle cramps, anxiety, pruritus, increased sputum, dry mouth.
Potentially Fatal: Paradoxical bronchospasm.
Drug Interactions
Increased risk of ventricular arrhythmia w/ drugs that prolong QT-interval (e.g. quinidine, disopyramide, procainamide, phenothiazines, antihistamines, erythromycin). Increased adverse effects w/ other sympathomimetic drugs. Increased CV effects w/ MAOIs, macrolides, or TCAs. Increased risk of hypokalaemia w/ xanthine derivatives, steroids, or non K-sparing diuretics. Increased risk of arrhythmias w/ concomitant anaesth w/ halogenated hydrocarbons. Increased bronchodilating effects w/ anticholinergic drugs. Antagonistic effect w/ β-blockers.
CIMS Class
Antiasthmatic & COPD Preparations
ATC Classification
R03AC13 - formoterol ; Belongs to the class of adrenergic inhalants, selective beta-2-adrenoreceptor agonists. Used in the treatment of obstructive airway diseases.
Disclaimer: This information is independently developed by CIMS based on formoterol from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in